Nuclease in Medical Technology

Researchers Create First Targeted Knockout Rats Using Zinc Finger Nuclease Technology

... Open Monoclonal Technology, Inc. (OMT) and INSERM today announced the creation of the first genetically modified mammals developed using zinc finger nuclease (ZFN) technology. (Photo: http://www.newscom.com/cgi-bin/prnh/20090723/CG50357 ) In a paper published in the July 24, 2009 issue ...

Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech

... of cell lines with novel characteristics for pharmaceutical protein production purposes using Sangamo's proprietary zinc finger DNA-binding protein nuclease (ZFN) technology. Genentech scientists demonstrated the successful knockout of two preselected genes in a Chinese hamster ovary (CHO) cell line. The ...

Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives

... to be nothing short of revolutionary for research applications," commented Dr. Smoller. "Marketed under the trademark CompoZr, the zinc finger nuclease (ZFN) technology makes available, for the first time, simple, efficient genomic editing. CompoZr(TM) ZFN reagents can be used to efficiently create ...

Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial

... RNA ('siRNA') molecules, AtuRNAi, which provide a number of advantages over conventional siRNA molecules, including increased stability against nuclease degradation. In addition, the Company has developed a proprietary systemic delivery system, AtuPLEX. This system enables the functional delivery of ...

Silence Therapeutics Announces Board Changes

... RNA ('siRNA') molecules, AtuRNAi, which provide a number of advantages over conventional siRNA molecules, including increased stability against nuclease degradation. In addition, the Company has developed a proprietary systemic delivery system, AtuPLEX. This system enables the functional delivery of ...

Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting

... and should therefore be available to destroy tumor cells. The aim of the collaboration is to use Sangamo's zinc finger DNA-binding protein nuclease (ZFN) gene modification technology to delete the GR in T-cells engineered to express the zetakine. The specific deletion of GR in the ...

Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on Targeted, Systemic Delivery of siRNA

... formulation self assembles into nanoparticles that protect the siRNA from nuclease degradation in serum. One important result of the study was the lack of a ... approximately 50-80 nm diameter that fully protect the siRNA from nuclease degradation in serum. The siRNA delivery system has been designed to allow ...

Calando Pharmaceuticals Publishes the First Non-Human Primate Study on Targeted, Systemic Delivery of siRNA in National Academy of Sciences Journal

... "backbone" of the siRNA. The polymer and siRNA self-assemble into nanoparticles of approximately 50-80 nm diameter that fully protect the siRNA from nuclease degradation in serum. The siRNA delivery system has been designed to allow for intravenous injection. Upon delivery to the target cell, the targeting ...

Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect with Lead RNAi Candidate

... "backbone" of the siRNA. The polymer and siRNA self-assemble into nanoparticles of approximately 50-80 nm diameter that fully protect the siRNA from nuclease degradation in serum. The siRNA delivery system has been designed to allow for intravenous injection. Upon delivery to the target cell, the targeting ...

Arrowhead Subsidiary Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect with Lead RNAi Candidate

... of the siRNA. The polymer and siRNA self-assemble into nanoparticles of approximately 50-80 nm in diameter that fully protect the siRNA from nuclease degradation in serum. The siRNA delivery system has been designed to allow for intravenous injection. Upon delivery to the target cell, the targeting ...

Calando Pharmaceuticals Announces Preclinical Efficacy and Safety Data of Targeted, Systemic Delivery of siRNA at AACR Annual Meeting

... "backbone" of the siRNA. The polymer and siRNA self-assemble into nanoparticles of approximately 50-80 nm diameter that fully protect the siRNA from nuclease degradation in serum. The siRNA delivery system has been designed to allow for intravenous injection. Upon delivery to the target cell, the targeting ...

Geron's Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial

... or expressed transiently at low levels in most normal adult tissues. GRN163L is a short chain oligonucleotide that is unique in its resistance to nuclease digestion in blood and tissues and its very high affinity and specificity for telomerase. The molecule has superior cellular and tissue penetration ...